Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Accolate
Zafirlukast is a leukotriene receptor antagonist (LTRA) used to prevent and treat asthma and exercise-induced bronchospasm (EIB). It works by blocking the action of leukotrienes, which are substances released by the body during an allergic reaction that cause inflammation and narrowing of the airways. Zafirlukast belongs to a class of medications that help control asthma symptoms by reducing airway inflammation.
For the prevention and long-term treatment of asthma and exercise-induced bronchospasm (EIB).
Outcome:
Increased risk of bleeding
Mechanism:
Zafirlukast can inhibit the metabolism of warfarin.
Outcome:
Additive bronchodilatory effects
Mechanism:
Both drugs act on different pathways to improve airflow.
Outcome:
Decreased zafirlukast absorption
Mechanism:
Food can delay the absorption of zafirlukast.
Most likely new formulation: Controlled-release formulation (Year: 2026, 30% confidence)
Based on historical usage patterns and current regulatory trends, there is a low ( <5%) likelihood of zafirlukast being withdrawn from the market.
Leukotriene Receptor Antagonist
Leukotriene Inhibitor